Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Outlook Therapeutics (OTLK) EBIAT (2016 - 2025)

Historic EBIAT for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$13.5 million.

  • Outlook Therapeutics' EBIAT changed N/A to -$13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$93.3 million, marking a year-over-year change of. This contributed to the annual value of -$62.4 million for FY2025, which is 1717.18% up from last year.
  • Per Outlook Therapeutics' latest filing, its EBIAT stood at -$13.5 million for Q4 2025.
  • In the past 5 years, Outlook Therapeutics' EBIAT registered a high of -$13.3 million during Q3 2025, and its lowest value of -$46.4 million during Q1 2025.